TSE:4151Pharmaceuticals
Does Ending Rocatinlimab Trials Over Safety Concerns Change The Bull Case For Kyowa Kirin (TSE:4151)?
In early March 2026, Kyowa Kirin Co., Ltd. announced it would discontinue all clinical trials of rocatinlimab, an investigational anti-OX40 antibody for moderate-to-severe atopic dermatitis, prurigo nodularis, and asthma, following a planned safety review conducted with partner Amgen.
The decision was driven by emerging malignancy signals, including confirmed and suspected cases of Kaposi’s sarcoma that, despite low overall incidence, raised plausible mechanistic concerns about OX40 pathway...